ESR1 and breast carcinoma: Recurrent ERα mutations, ERα fusion proteins or postranscriptional modifications of ERα can circumvent the binding of inhibitory drugs to ERα or lead to constitutively active/ligand-independent ERα proteins thereby making breast cancer cells resistant to drugs such as SERMs (e.g. tamoxifen) and AIs.